Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human Noggin/NOG Protein, Fc Tag, 100µg  

Recombinant human Noggin/NOG Protein, Fc Tag, 100µg

Recombinant Human Noggin /NOG Protein, Gln 28 - Cys 232 was produced in human 293 cells (HEK293), Fc Tag

Synonym
recombinant human protein, Noggin, NOG, SYM1, SYM-1, SYNS1, SYNS-1

More details

NON-H5257-100

Availability: within 7 days

408,00 €

Background
Noggin is also known as NOG,SYM1, SYNS1 and is a secreted homodimeric glycoprotein whose scaffold contains a cystineknot topology similar to that of BMPs.Secreted Noggin probably remains close to the cell surface due to its binding of
heparincontaining proteoglycans.Noggin inhibits TGF-β signal transduction by binding to TGF-β family ligands and preventing
them from binding to their corresponding receptors. Noggin plays a key role in neural induction by inhibiting BMP4, along with
other TGF-β signaling inhibitors such as chordin and follistatin. Mouse knockout experiments have demonstrated that noggin
also plays a crucial role in bone development, joint formation, and neural tube fusion. During embryogenesis, Noggin
antagonizes specific BMPs at defined times, for example, during neural tube, somite and cardiomyocyte growth and patterning.
During skeletal development, Noggin prevents chondrocyte hyperplasia, thus allowing proper formation of joints. During culture
of human embryonic stem cells (hESC) or neural stem cells under certain conditions, addition of Noggin to antagonize BMP
activity may allow stem cells to proliferate while maintaining their undifferentiated state, or alternatively, to differentiate into
dopaminergic neurons Noggin also appears to maintain adult stem cell populations in vivo, for example, maintaining neural
stem cells within the hippocampus.

Source
Recombinant Human Noggin /NOG Protein, With C-Fc Tag (rhNoggin-Fc) Gln 28 - Cys 232 (Accession # NP_005441) was produced in human 293 cells (HEK293).

Molecular Characterization
rhNoggin-Fc was fused with Fc region of human IgG1 at C-terminus and has a calculated MW of 49.8 kDa expressed. The predicted N-terminus is Gln 28 Protein migrates as 58-62 kDa in reduced SDS-PAGE resulting from glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhNoggin-Fc by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
N/A

References

(1) Valenzuela, D.M. et al. 1995, J. Neurosci. 15:6077
(2) Groppe, J. et al. 2002, Nature 420:636
(3) Itsykson, P. et al. 2005, Mol. Cell. Neurosci. 30:24
(4) Xu, R.H.et al. 2005, Nat. Methods 2:185
(5) Bonaguidi, M.A. et al. 2008, J. Neurosci. 28:9194